ISBN: 9783631663813 - pharma m&a versus alliances and its underlying value drivers: are m&a or alliances the right therapy for an ailing pharmaceutical industry?- a capital ... (corporate finance and governance, band 15) (8 Ergebnisse)

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

Pp. Zustand: Wie neu. 201 S. : graph. Darst. ; 22 cm, 360 g Tadellos. - Content -- Table Index 9 -- Graph Index 11 -- A. Introduction 15 -- I. The Pharmaceutical Industry and Its Paradigm Shift 19 -- 1.1 History 19 -- 1.2 Market Analysis 20 -- 1.2.1 Market Definition 20 -- 1.2.2 Market Size and Market Growth 21 -- 1.2.3 BigPharma 21 -- 1.2.4 Geographic Segmentation 22 -- 1.2.5 Therapeutic Segmentation 24 -- 1.2.6 Blockbusters 25 -- 1.3 Innovation and Innovation Crisis 26 -- 1.3.1 R&D Productivity 27 -- 1.3.2 R&D Process 28 -- 1.3.3 R&D Pipeline 30 -- 1.4 Patent Protection and Patent Cliff 32 -- 1.5 Generics 34 -- 1.6 Biotechnology 37 -- 1.7 Pricing, Funding and Governmental Austerity Measures 41 -- 1.8 Restructuring Programs 43 -- 1.9 Summary 44 -- II. The Pharmaceutical Industry and Mergers & Acquisitions 47 -- II.1 M&A Deal Rationales 47 -- II.1.1 Scale & Synergy Deals 48 -- II.1.2 Innovation Deals 50 -- II.1.3 Pharmerging Market Deals 51 -- II.1.4 Diversification Deals 52 -- 11.2 Status of Consolidation 53 -- 11.3 M&A Activity Development 54 -- 11.4 Top Pharmaceutical M&A Transactions 56 -- 11.5 Summary 59 -- III. Value Creation in Pharmaceutical M&A and its -- underlying Value Drivers 61 -- III.1 Literature Review and Literature Contribution 61 -- 111.2 Data Sample 62 -- 111.3 Deal Statistics 65 -- 111.4 Research Methodology. 66 -- 111.5 Acquirers'Wealth Effects 73 -- 111.6 Univariate Subsample Analyses of M&A Value Drivers 74 -- III.6.1 Target's Business Nature 74 -- 111.6.2 Geographical Focus 80 -- 111.6.3 Pharmaceutical Merger Waves 87 -- 111.6.4 Relative Transaction Size 89 -- 111.6.5 Method of Payment 92 -- 111.6.6 Target's R&D Intensity 94 -- 111.6.7 Strategic Alliances Pre-Merger 96 -- 111.6.8 M&A Experience 100 -- 111.6.9 Relative Price Level 102 -- 111.6.10 Target's Financials 106 -- 111.7 Multivariate Analysis of M&A Value Drivers 113 -- 111.8 Conclusions and Recommendations 117 -- IV. The Pharmaceutical Industry and Alliances 119 -- IV.1 Strategic Alliances 119 ISBN 9783631663813 Sprache: Englisch Gewicht in Gramm: 315.…

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

Zustand: New. In English.

Zustand: New. This study analyzes 229 M&A and 120 in-licensing deals in the pharmaceutical industry. The author shows from a capital market perspective that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able to create value. Significant determinants of success for both strategies are derived. Series: Corporate Finance and Governance. Num Pages: 201 pages. BIC Classification: KCA; KJM; KJU; KJVG; MB. Category: (P) Professional & Vocational. Dimension: 154 x 215 x 17. Weight in Grams: 362. . 2015. New. hardcover. . . . . Books ship from the US and Ireland.…

Zustand: New. pp. 201.

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - From a capital market perspective, the author analyzes Merger and Acquisitions transactions (M&A) and in-licensings in the pharmaceutical industry between 1998 and 2012. Utilizing the event study methodology, the volume shows that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able to create value. But what are the underlying value drivers which make a deal a success or a failure story The author derives significant innovative determinants of success for both strategies.; Dissertationsschrift.…

Zustand: gut. Pharma M&A versus alliances and its underlying value drivers In deutscher Sprache. pages.